Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Jul 8

PMID 35799791

Authors

Yinqiang Zhang

Fen Zhou

Zhuolin Wu

Yingnan Li

Chenggong Li

Mengyi Du

Wenjing Luo

Haiming Kou

Cong Lu

Heng Mei

Affiliations

Soon will be listed here.

Abstract

Clinical Trial Registration: www.clinicaltrials.gov, NCT02965092 and NCT04008251.

Citing Articles

A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings.

Treon S, Kotton C, Park D, Moranzoni G, Lemvigh C, Gathe Jr J Front Immunol. 2025; 15:1369619.

PMID: 39906744 PMC: 11791645. DOI: 10.3389/fimmu.2024.1369619.

Rapidly Manufactured CAR-T with Conserved Cell Stemness and Distinctive Cytokine-Secreting Profile Shows Improved Anti-Tumor Efficacy.

Tsao S, Gu M, Xiong Q, Deng Y, Deng T, Fu C Vaccines (Basel). 2025; 12(12.

PMID: 39772010 PMC: 11680398. DOI: 10.3390/vaccines12121348.

Successful Application of Tocilizumab in a Patient With Neoadjuvant Immunochemotherapy-Induced Cytokine Release Syndrome.

Minami S, Kawashima Y, Munakata Y, Matsuno M, Hara S, Yamazaki Y Cancer Rep (Hoboken). 2024; 7(7):e2145.

PMID: 39051558 PMC: 11270316. DOI: 10.1002/cnr2.2145.

IL-10 plus the EASIX score predict bleeding events after anti-CD19 CAR T-cell therapy.

Wang X, Li C, Luo W, Zhang Y, Huang Z, Xu J Ann Hematol. 2023; 102(12):3575-3585.

PMID: 37814134 PMC: 10640490. DOI: 10.1007/s00277-023-05477-y.

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies.

Zhang Y, Li C, Du M, Jiang H, Luo W, Tang L Blood Cancer J. 2023; 13(1):61.

PMID: 37095094 PMC: 10125858. DOI: 10.1038/s41408-023-00822-w.

References

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

Lee D, Gardner R, Porter D, Louis C, Ahmed N, Jensen M . Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-95. PMC: 4093680. DOI: 10.1182/blood-2014-05-552729. View

Parker K, Migliorini D, Perkey E, Yost K, Bhaduri A, Bagga P . Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies. Cell. 2020; 183(1):126-142.e17. PMC: 7640763. DOI: 10.1016/j.cell.2020.08.022. View

Le R, Li L, Yuan W, Shord S, Nie L, Habtemariam B . FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. Oncologist. 2018; 23(8):943-947. PMC: 6156173. DOI: 10.1634/theoncologist.2018-0028. View

Thompson J, Schneider B, Brahmer J, Andrews S, Armand P, Bhatia S . NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw. 2020; 18(3):230-241. DOI: 10.6004/jnccn.2020.0012. View

Jiang H, Liu L, Guo T, Wu Y, Ai L, Deng J . Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy. Ann Hematol. 2019; 98(7):1721-1732. DOI: 10.1007/s00277-019-03685-z. View

Gardner R, Ceppi F, Rivers J, Annesley C, Summers C, Taraseviciute A . Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood. 2019; 134(24):2149-2158. PMC: 6908832. DOI: 10.1182/blood.2019001463. View

Juluri K, Wu Q, Voutsinas J, Hou J, Hirayama A, Mullane E . Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. Blood Adv. 2021; 6(7):2055-2068. PMC: 9006285. DOI: 10.1182/bloodadvances.2020004142. View

Oluwole O, Bouabdallah K, Munoz J, de Guibert S, Vose J, Bartlett N . Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol. 2021; 194(4):690-700. PMC: 8457222. DOI: 10.1111/bjh.17527. View

10.

Topp M, van Meerten T, Houot R, Minnema M, Bouabdallah K, Lugtenburg P . Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol. 2021; 195(3):388-398. PMC: 9293158. DOI: 10.1111/bjh.17673. View

11.

Lee D, Santomasso B, Locke F, Ghobadi A, Turtle C, Brudno J . ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2018; 25(4):625-638. DOI: 10.1016/j.bbmt.2018.12.758. View

12.

Gust J, Finney O, Li D, Brakke H, Hicks R, Futrell R . Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy. Ann Neurol. 2019; 86(1):42-54. PMC: 9375054. DOI: 10.1002/ana.25502. View

13.

Gust J, Hay K, Hanafi L, Li D, Myerson D, Gonzalez-Cuyar L . Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discov. 2017; 7(12):1404-1419. PMC: 5718945. DOI: 10.1158/2159-8290.CD-17-0698. View

14.

Park J, Riviere I, Gonen M, Wang X, Senechal B, Curran K . Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):449-459. PMC: 6637939. DOI: 10.1056/NEJMoa1709919. View

15.

Mehta P, Fiorenza S, Koldej R, Jaworowski A, Ritchie D, Quinn K . T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy. Front Immunol. 2021; 12:780442. PMC: 8658247. DOI: 10.3389/fimmu.2021.780442. View

16.

Korell F, Schubert M, Sauer T, Schmitt A, Derigs P, Weber T . Infection Complications after Lymphodepletion and Dosing of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or B Cell Non-Hodgkin Lymphoma. Cancers (Basel). 2021; 13(7). PMC: 8038233. DOI: 10.3390/cancers13071684. View

17.

Gardner R, Finney O, Annesley C, Brakke H, Summers C, Leger K . Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017; 129(25):3322-3331. PMC: 5482103. DOI: 10.1182/blood-2017-02-769208. View

18.

Kim J, Chuang H, Wolf N, Nicolai C, Raulet D, Saijo K . Tumor-induced disruption of the blood-brain barrier promotes host death. Dev Cell. 2021; 56(19):2712-2721.e4. PMC: 8511098. DOI: 10.1016/j.devcel.2021.08.010. View

19.

Maude S, Frey N, Shaw P, Aplenc R, Barrett D, Bunin N . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-17. PMC: 4267531. DOI: 10.1056/NEJMoa1407222. View

20.

Lee D, Kochenderfer J, Stetler-Stevenson M, Cui Y, Delbrook C, Feldman S . T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2014; 385(9967):517-528. PMC: 7065359. DOI: 10.1016/S0140-6736(14)61403-3. View